NDRA
Price
$5.73
Change
-$0.32 (-5.29%)
Updated
Nov 13 closing price
NVRO
Price
$4.45
Change
-$0.61 (-12.06%)
Updated
Nov 13 closing price
97 days until earnings call
Ad is loading...

NDRA vs NVRO

Header iconNDRA vs NVRO Comparison
Open Charts NDRA vs NVROBanner chart's image
ENDRA Life Sciences
Price$5.73
Change-$0.32 (-5.29%)
Volume$54.49K
CapitalizationN/A
NEVRO
Price$4.45
Change-$0.61 (-12.06%)
Volume$1.38M
CapitalizationN/A
NDRA vs NVRO Comparison Chart
Loading...
NDRA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NVRO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NDRA vs. NVRO commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NDRA is a StrongSell and NVRO is a Hold.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (NDRA: $5.79 vs. NVRO: $4.45)
Brand notoriety: NDRA and NVRO are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NDRA: 17% vs. NVRO: 267%
Market capitalization -- NDRA: $4.44M vs. NVRO: $525.59M
NDRA [@Medical Specialties] is valued at $4.44M. NVRO’s [@Medical Specialties] market capitalization is $525.59M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NDRA’s FA Score shows that 0 FA rating(s) are green whileNVRO’s FA Score has 0 green FA rating(s).

  • NDRA’s FA Score: 0 green, 5 red.
  • NVRO’s FA Score: 0 green, 5 red.
According to our system of comparison, both NDRA and NVRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NDRA’s TA Score shows that 1 TA indicator(s) are bullish while NVRO’s TA Score has 6 bullish TA indicator(s).

  • NDRA’s TA Score: 1 bullish, 7 bearish.
  • NVRO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NVRO is a better buy in the short-term than NDRA.

Price Growth

NDRA (@Medical Specialties) experienced а -24.53% price change this week, while NVRO (@Medical Specialties) price change was -23.01% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.86%. For the same industry, the average monthly price growth was +1.31%, and the average quarterly price growth was -3.19%.

Reported Earning Dates

NDRA is expected to report earnings on May 15, 2023.

NVRO is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Medical Specialties (-0.86% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVRO($526M) has a higher market cap than NDRA($4.44M). NVRO YTD gains are higher at: -79.322 vs. NDRA (-99.844). NDRA has higher annual earnings (EBITDA): -12.09M vs. NVRO (-78.31M). NVRO has more cash in the bank: 323M vs. NDRA (3.34M). NDRA has less debt than NVRO: NDRA (434K) vs NVRO (216M). NVRO has higher revenues than NDRA: NVRO (425M) vs NDRA (0).
NDRANVRONDRA / NVRO
Capitalization4.44M526M1%
EBITDA-12.09M-78.31M15%
Gain YTD-99.844-79.322126%
P/E RatioN/A147.06-
Revenue0425M-
Total Cash3.34M323M1%
Total Debt434K216M0%
FUNDAMENTALS RATINGS
NDRA vs NVRO: Fundamental Ratings
NDRA
NVRO
OUTLOOK RATING
1..100
304
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9793
PRICE GROWTH RATING
1..100
9864
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NDRA's Valuation (57) in the Biotechnology industry is in the same range as NVRO (82) in the Medical Specialties industry. This means that NDRA’s stock grew similarly to NVRO’s over the last 12 months.

NDRA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVRO (100) in the Medical Specialties industry. This means that NDRA’s stock grew similarly to NVRO’s over the last 12 months.

NVRO's SMR Rating (93) in the Medical Specialties industry is in the same range as NDRA (97) in the Biotechnology industry. This means that NVRO’s stock grew similarly to NDRA’s over the last 12 months.

NVRO's Price Growth Rating (64) in the Medical Specialties industry is somewhat better than the same rating for NDRA (98) in the Biotechnology industry. This means that NVRO’s stock grew somewhat faster than NDRA’s over the last 12 months.

NVRO's P/E Growth Rating (98) in the Medical Specialties industry is in the same range as NDRA (100) in the Biotechnology industry. This means that NVRO’s stock grew similarly to NDRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NDRANVRO
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
71%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Ad is loading...
NDRA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NVRO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSAFX9.340.01
+0.11%
Hussman Strategic Allocation
AEUDX9.53N/A
N/A
American Century Equity Income R6
JPVRX14.67N/A
N/A
JPMorgan Developed International ValueR5
ARABX15.74N/A
N/A
Aristotle Small Cap Eq A
ACADX11.64-0.10
-0.85%
American Century Emerging Markets G

NDRA and

Correlation & Price change

A.I.dvisor tells us that NDRA and ICUI have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NDRA and ICUI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NDRA
1D Price
Change %
NDRA100%
-4.31%
ICUI - NDRA
24%
Poorly correlated
-1.80%
CNMD - NDRA
23%
Poorly correlated
+1.18%
LAB - NDRA
22%
Poorly correlated
-9.76%
NVRO - NDRA
22%
Poorly correlated
-12.06%
PSNL - NDRA
22%
Poorly correlated
-9.08%
More

NVRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVRO has been loosely correlated with AZTA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NVRO jumps, then AZTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVRO
1D Price
Change %
NVRO100%
-12.06%
AZTA - NVRO
50%
Loosely correlated
-3.24%
CRL - NVRO
49%
Loosely correlated
-4.35%
INSP - NVRO
47%
Loosely correlated
-4.49%
TNDM - NVRO
43%
Loosely correlated
-4.60%
ICUI - NVRO
40%
Loosely correlated
-1.80%
More